You are here

Distribution of Risk Factors in Ocular Hypertension and Open-Angle Glaucoma Patients in Canada

Last updated on November 9, 2019

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Calgary, Alberta, T3E 7M8 Canada
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Open-Angle Glaucoma, Ocular Hypertension
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Subjects diagnosed at study visit or within 3 months of visit with OH

- OAG (to include POAG, NTG, pigmentary and pseudoexfoliation glaucoma)

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- No prior treatment for OH or OAG

- No prior ocular surgery or history of ocular trauma

NCT00334750
Pfizer
Completed
Distribution of Risk Factors in Ocular Hypertension and Open-Angle Glaucoma Patients in Canada

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Descriptive Information
Brief TitleDistribution of Risk Factors in Ocular Hypertension and Open-Angle Glaucoma Patients in Canada
Official TitleDistribution of Risk Factors Amongst Ocular Hypertension and Open-Angle Glaucoma Patients in Canada
Brief SummaryThis descriptive, non-interventional study will collect information on the presence of risk factors in newly diagnosed ocular hypertension and open-angle glaucoma patients in Canada.
Detailed DescriptionNot Provided
Study TypeObservational
Study DesignObservational Model: Cohort
Time Perspective: Prospective
Target Follow-Up DurationNot Provided
BiospecimenNot Provided
Sampling MethodNon-Probability Sample
Study PopulationCanadian population
Condition
  • Glaucoma, Open-Angle
  • Ocular Hypertension
InterventionOther: There is no intervention in this study.
This study is collecting information on the presence of risk factors in new diagnosed OH and OAG patients in Canada.
Study Groups/CohortsThere is no intervention in this study
This study is collecting information on the presence of risk factors in new diagnosed OH and OAG patients in Canada.
Intervention: Other: There is no intervention in this study.
Publications *Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment StatusCompleted
Actual Enrollment
 (submitted: September 8, 2010)
410
Original Enrollment
 (submitted: June 5, 2006)
400
Actual Study Completion DateApril 2009
Actual Primary Completion DateApril 2009   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Subjects diagnosed at study visit or within 3 months of visit with OH
  • OAG (to include POAG, NTG, pigmentary and pseudoexfoliation glaucoma)

Exclusion Criteria:

  • No prior treatment for OH or OAG
  • No prior ocular surgery or history of ocular trauma
Sex/Gender
Sexes Eligible for Study:All
Ages18 Years and older   (Adult, Older Adult)
Accepts Healthy VolunteersNo
ContactsContact information is only displayed when the study is recruiting subjects
Listed Location CountriesCanada
Removed Location Countries  
 
Administrative Information
NCT NumberNCT00334750
Other Study ID NumbersA6111125
Has Data Monitoring CommitteeNo
U.S. FDA-regulated ProductNot Provided
IPD Sharing StatementNot Provided
Responsible PartyDirector, Clinical Trial Disclosure Group, Pfizer Inc
Study SponsorPfizer
CollaboratorsNot Provided
Investigators
Study Director:Pfizer CT.gov Call CenterPfizer
PRS AccountPfizer
Verification DateSeptember 2010

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now